NASDAQ:CUE

Cue Biopharma Stock Insider Trading

etoro logo Buy CUE
*Your capital is at risk
$26.84
-3.56 (-11.71%)
At Close: Jul 31, 2026

Cue Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 12.6M and sold 0 CUE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 12.6M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Jun 04, 2025
Buy
Common Stock
J-Other
Broadfoot Jill Marie
Insider
Other 0
Value: $0
Jun 04, 2025
Buy
Stock Option (right to buy)
A-Award
Broadfoot Jill Marie
Director
Director 48 800
Value: $30.3K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Millar Kerri-ann
Chief Financial Officer
C-Suite Officer 200 000
Value: $198.0K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Passeri Daniel R
Chief Executive Officer
CEO / President 450 000
Value: $445.5K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Baker Daniel G.
Chief Development Officer
Officer 100 000
Value: $99.0K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Sandercock Colin
SVP, General Counsel
Officer 200 000
Value: $198.0K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Warren Lucinda
Chief Business Officer
Officer 250 000
Value: $247.5K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Levisetti Matteo
Chief Medical Officer
Officer 250 000
Value: $247.5K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Levisetti Matteo
Chief Medical Officer
Officer 250 000
Value: $247.5K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Warren Lucinda
Chief Business Officer
Officer 250 000
Value: $247.5K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Sandercock Colin
SVP, General Counsel
Officer 200 000
Value: $198.0K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Baker Daniel G.
Chief Development Officer
Officer 100 000
Value: $99.0K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Passeri Daniel R
Chief Executive Officer
CEO / President 450 000
Value: $445.5K
Mar 21, 2025
Buy
Stock Option (right to buy)
A-Award
Millar Kerri-ann
Chief Financial Officer
C-Suite Officer 200 000
Value: $198.0K
Mar 10, 2025
Buy
Stock Option (right to buy)
A-Award
Sarraf Pasha
Director
Director 48 800
Value: $50.3K
Mar 10, 2025
Buy
Common Stock
J-Other
Sarraf Pasha
Insider
Other 0
Value: $0
Mar 10, 2025
Buy
Common Stock
J-Other
Sarraf Pasha
Insider
Other 0
Value: $0
Mar 10, 2025
Buy
Stock Option (right to buy)
A-Award
Sarraf Pasha
Director
Director 48 800
Value: $50.3K
Jan 02, 2025
Buy
Stock Option (right to buy)
A-Award
Verheyen Patrick
Director
Director 24 400
Value: $26.6K
Jan 02, 2025
Buy
Stock Option (right to buy)
A-Award
Garzone Pamela
Director
Director 24 400
Value: $26.6K
Jan 02, 2025
Buy
Stock Option (right to buy)
A-Award
Morich Frank
Director
Director 24 400
Value: $26.6K
Jan 02, 2025
Buy
Stock Option (right to buy)
A-Award
Driscoll Frederick W
Director
Director 24 400
Value: $26.6K
Jan 02, 2025
Buy
Stock Option (right to buy)
A-Award
Kiener Peter A
Director
Director 24 400
Value: $26.6K
Jan 02, 2025
Buy
Stock Option (right to buy)
A-Award
Kiener Peter A
Director
Director 24 400
Value: $26.6K
Jan 02, 2025
Buy
Stock Option (right to buy)
A-Award
Driscoll Frederick W
Director
Director 24 400
Value: $26.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CUE BIOPHARMA INC.
Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-10...
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE